Single-use Bioprocessing Market Size & Share 2026-2035

Single-Use Bioprocessing Market Size

The single-use bioprocessing market was valued at USD 13.9 billion in 2025 and is projected to reach USD 35.8 billion by 2035, expanding at a CAGR of approximately 10.1%. Demand is anchored in biologics manufacturing, where product portfolios are becoming broader and more fragmented. The FDA approved 19 biosimilars in 2024, compared with five in 2023 ^{[1]U.S. Food and Drug Administration, Biosimilar Product Information, fda.gov}, while biologics represented 41% of European pharmaceutical expenditure in 2024.

Single-use systems replace reusable process-contact equipment with pre-sterilized bioreactors, bags, tubing, filters, mixing assemblies, connectors, and sensors. Their relevance is strongest where manufacturers need rapid campaign changeovers, modular capacity, or facility designs that can accommodate several biologic modalities. Peer-reviewed research identifies lower facility complexity, faster construction, and greater operating flexibility as central advantages relative to stainless-steel installations ^{[2]Annual Reviews, Transformation of biomanufacturing by single-use systems and technology, annualreviews.org}. Survey evidence also places single-use technology in at least 85% of pre-commercial-scale biopharma manufacturing and associates it with reduced water, labor, space, and energy requirements relative to stainless-steel systems.

The advantage is conditional. Single-use adoption shifts cost from fixed infrastructure to recurring assemblies, qualification work, and waste management. Suppliers that can document material performance, maintain component availability, and support process transfer across development and commercial scales are therefore positioned more favorably than suppliers offering isolated consumables.

The market covers disposable, pre-sterilized technologies used in biologics, vaccine, and advanced-therapy manufacturing, including single-use bioreactors, bags and containers, tubing assemblies, connectors and fittings, filtration devices, mixing systems, sensors and probes, and sampling systems.

Key Drivers

Rising demand for biologics and biosimilars

Loss-of-exclusivity cycles are widening the addressable manufacturing base for biosimilars. IQVIA estimates that 69 biologics are expected to lose exclusivity in Europe by 2030, representing approximately EUR 28 billion in cumulative value. A larger number of molecules does not automatically require large, dedicated plants; many biosimilar entrants instead need adaptable capacity that supports process development, clinical supply, and commercial launch without committing capital to a single molecule. Single-use upstream and fluid-management systems reduce the threshold for those investments.

Personalized medicines and cell and gene therapies

Cell, gene, and RNA therapy manufacturing favors closed, scalable workflows because batch sizes are often smaller and product segregation is critical. As of the fourth quarter of 2024, 33 gene therapies, 72 non-genetically modified cell therapies, and 35 RNA therapies had received global approvals, alongside more than 3,200 active clinical trials ^{[3]American Society of Gene & Cell Therapy and Citeline, Gene, Cell, & RNA Therapy Landscape Report - Q4 2024, asgct.org}. The resulting demand is particularly relevant to smaller bioreactors, bags, tubing assemblies, sensors, and sterile connectors, where closed processing can reduce interventions during sensitive manufacturing steps.

Outsourcing to CDMOs and CMOs

CDMOs must accommodate multiple clients, product formats, and production schedules while preserving segregation and turnaround speed. Industry research indicates that multi-year master service agreements have become standard in biologics outsourcing, and KPMG expects biopharma services to outpace broader pharmaceutical growth through 2028. Flexible single-use configurations allow CDMOs to reconfigure suites between campaigns, making the technology a capacity-utilization tool as well as a contamination-control measure.

Reduced risk of cross-contamination

Pre-sterilized disposable flow paths eliminate much of the cleaning and sterilization work required between batches. ISPE notes that single-use technology has significantly reduced contamination risk in manufacturing equipment while improving flexibility. The commercial effect is most pronounced for multi-product plants, where a deviation or prolonged cleaning validation cycle can delay the next client campaign and reduce suite availability.

Lower capital investment than stainless-steel systems

Single-use designs can reduce initial infrastructure requirements, especially where manufacturing volumes and product lifecycles remain uncertain. A comparative facility example cited by BioProcess Online estimated a six-by-2,000-liter single-use facility at approximately USD 70 million versus USD 200 million for a stainless-steel equivalent. The economics are strongest where moderate production volumes, high titers, and rapid deployment offset the higher recurring cost of disposable assemblies.

Key Restraints

Extractables and leachables

The qualification burden for polymer-based components is rising. The draft ICH Q3E guideline requires quality-risk assessment for extractables and leachables from both single-use and multi-use manufacturing components and systems ^{[4]U.S. Food and Drug Administration and International Council for Harmonisation, Q3E Guideline for Extractables and Leachables, fda.gov}. In parallel, USP <665> and <1665> are scheduled to become effective on May 1, 2026. This changes procurement from a component-price exercise into a documentation and comparability exercise, particularly for manufacturers with established process validation packages.

Environmental concerns related to plastic waste generation

Single-use systems reduce water and cleaning-chemical use, but they generate mixed-material waste that is difficult to recycle at scale. BioPhorum identifies the increased volume of plastic waste from wider SUT use and notes that material complexity creates recycling challenges. The restraint is becoming more consequential in Europe and North America, where environmental reporting expectations and corporate sustainability commitments are more likely to influence supplier qualification and waste-handling contracts.

High recurring consumables cost

The cost advantage of single-use systems is front-loaded in capital expenditure; the operating model relies on recurring purchases of proprietary or qualified assemblies. In BioPlan's 2024 survey, 32.3% of respondents selected lower-cost single-use devices as their leading upstream R&D priority, while satisfaction with single-use-system cost stood at 46.4%. Price sensitivity is particularly acute for emerging biologics manufacturers and for regions where lower financing capacity makes recurring imported consumable costs more visible than avoided plant capital.

Cost pressure creates a separate but related risk. A facility may favor single-use equipment during initial capacity planning, then seek to standardize vendors, reduce assembly complexity, or reconsider reusable equipment once commercial volumes become predictable. Suppliers that reduce qualification duplication, improve component durability, and support waste solutions can protect demand that would otherwise be exposed to recurring-cost scrutiny.

Single-Use Bioprocessing Market Segment Analysis

By Product Type

Bags and containers generated USD 4.1 billion in 2025, making them the largest product category. Their breadth of use across media preparation, buffer storage, intermediate hold, product collection, and fluid transfer creates demand in both upstream and downstream operations. Their commercial importance also makes film performance, weld integrity, and supplier continuity central to customer risk management.

Single-use bioreactors represented USD 3.7 billion in 2025. Stirred-tank systems address conventional mammalian cell culture, wave-mixed systems support gentler cell handling and smaller-volume operations, and bubble-column designs serve selected aeration-intensive applications. The segment's growth depends on whether a supplier can preserve comparable process behavior from bench development through larger commercial scales. Thermo Fisher's 5L DynaDrive platform, designed to align reactor design and film from 1 to 5,000 liters, illustrates the market's emphasis on scale-transfer continuity.

Filtration devices accounted for USD 2.6 billion in 2025. Depth filtration, membrane filtration, tangential-flow filtration, ultrafiltration, and viral-clearance workflows make filtration strategically important beyond its revenue contribution. In downstream operations, qualification requirements and product yield make switching costs higher than for many fluid-transfer components. Tubing assemblies, connectors and fittings, mixing systems, sensors and probes, and sampling systems complete the closed workflow. Within sensors and probes, pH, dissolved-oxygen, pressure-and-flow, and other sensor types support process visibility without requiring repeated equipment disassembly.

By Workflow Stage

Upstream processing was valued at USD 7.4 billion in 2025. Cell culture development, media preparation, inoculation, and cell expansion require repeated use of bioreactors, bags, mixers, tubing, and in-line measurement components. The stage benefits most directly from the ability to introduce new capacity without building dedicated clean-in-place and steam-in-place infrastructure.

Downstream processing generated USD 4.6 billion in 2025. Harvesting, purification, concentration, sterile filtration, formulation, and fluid transfer require highly qualified flow paths because product loss, bioburden control, and regulatory comparability are significant. Final processing includes the assemblies and containment systems used in final formulation, filling preparation, and product handling, where closed operations can reduce exposure during late-stage processing.

By Application

Monoclonal antibodies represented USD 5.3 billion in 2025 and remained the largest application. Mature mAb processes can support standardization, but the breadth of molecule portfolios still favors flexible manufacturing suites over dedicated capacity for every product. Vaccine production generated USD 2.9 billion, with single-use systems supporting viral, protein-subunit, and mRNA process development where rapid configuration changes have material value.

Cell and gene therapy accounted for USD 2.3 billion in 2025. The application's growth is driven by the need for closed, segregated production environments for viral vectors, plasmid DNA, CAR-T, and related cell-processing workflows. Plasma-derived products and other biologics form additional demand pools, although process-specific validation requirements can slow conversion from reusable to disposable equipment.

By End Use

Biopharmaceutical and pharmaceutical companies held 61.5% of market revenue in 2025. Their purchasing decisions increasingly balance operating flexibility against lifecycle cost, material traceability, and regulatory documentation. CMOs and CROs generated USD 4.6 billion in 2025, reflecting the operational premium placed on rapid changeovers and multi-client scheduling. Academic and research institutes remain important early adopters because small-volume, development-stage work benefits from systems that can be configured without permanent plant infrastructure.

The strongest growth opportunities sit where technical flexibility is paired with disciplined standardization. Advanced-therapy manufacturers need modular systems, but they also need reproducible process behavior and clear documentation. CDMOs face the same tension at a larger operational scale. Vendors that simplify scale-up, change control, and cross-product platforming are likely to gain more durable positions than those competing only on the price of individual assemblies.

Single-Use Bioprocessing Market Regional Analysis

North America

North America held 38.30% of global revenue in 2025, equivalent to USD 5,269.89 million, and is projected to grow at a CAGR of 9.38% through 2035. The U.S. accounted for 94.45% of the regional market in 2025, or approximately USD 4,977.85 million, while Canada represented 5.55%. The U.S. position is supported by an extensive biologics development and approval base: CBER reported 17 biologics license application approvals and 26 BLA supplements in 2024 ^{[5]U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, CY 2024 Report from the Director, fda.gov}. North American demand therefore combines established commercial biologics capacity with investment in advanced manufacturing and cell-and-gene-therapy workflows.

Europe

Europe accounted for 27.20% of global revenue in 2025, or approximately USD 3,768.21 million, and is projected to expand at a CAGR of 9.66%. Germany, the UK, France, Spain, Italy, and the Netherlands provide the region's principal manufacturing and research footprint. Biosimilar activity supports demand, with Medicines for Europe reporting 44 EMA-authorized biosimilars in 2025. However, regional growth is moderated by investment competitiveness: EFPIA reported a 25% relative loss of European biopharma investment over two decades compared with other regions. This tension favors flexible modernization projects over major dedicated greenfield facilities.

Asia Pacific

Asia Pacific represented 25.40% of the global market in 2025, or approximately USD 3,518.84 million, and is expected to record the fastest regional CAGR of 11.47%. China, India, Japan, Australia, and South Korea are expanding biologics capacity through domestic investment, policy support, and CDMO growth. China invested USD 4.17 billion in biomanufacturing in 2024 and identified the sector for accelerated development in 2025 ^{[6]Pharma Manufacturing, China to double down on biomanufacturing investment in 2025, pharmamanufacturing.com}. India's biopharma sector expanded from USD 49.8 billion in 2022 to USD 53.8 billion in 2023, while India's BioE3 policy supports bio-foundry development. In Bengaluru, Syngene's 20-kiloliter single-use biologics facility was scheduled to become operational in the second half of 2024, demonstrating direct regional demand for flexible manufacturing infrastructure.

Latin America

Latin America accounted for 4.93% of global revenue in 2025 and is forecast to grow at a CAGR of 10.56%. Brazil, Mexico, and Argentina are supported by growing biosimilar policy activity and local production objectives. Brazil's ANVISA 2024–2027 strategic plan prioritizes biosimilar development, while Mexico's COFEPRIS established a biosimilars unit in 2024. The region's lower installed base makes modular, lower-capital systems attractive, although procurement can remain sensitive to imported consumable cost and local technical-service availability.

Middle East and Africa

Middle East and Africa held 4.17% of global revenue in 2025 and is projected to grow at a CAGR of 10.35%. Saudi Arabia, South Africa, and the UAE are the principal markets within the regional scope. Demand is linked to local pharmaceutical-production ambitions, vaccine-manufacturing interest, and healthcare modernization. Smaller initial production volumes favor technologies that avoid committing to large fixed stainless-steel plants, although limited local supply chains and specialist labor availability can constrain implementation speed.

Europe presents a more selective opportunity. Biosimilar activity and strong process expertise support demand, but investment pressure raises the value of capital-efficient modernization. Latin America and Middle East and Africa offer a different proposition: lower upfront infrastructure requirements are attractive, but consumables pricing, qualified distribution, and technical support determine whether that theoretical advantage converts into sustained adoption.

Single-Use Bioprocessing Market Share & Competitive Landscape

Competition is organized around the ability to supply interoperable, qualified workflow platforms rather than individual disposable components. Avantor Inc., Cellexus International Ltd., Celltainer Biotech BV, Danaher Corporation, Entegris Inc., Eppendorf SE, Getinge AB, Meissner Filtration Products Inc., Merck KGaA, Parker Hannifin Corporation, PBS Biotech Inc., Repligen Corporation, Saint-Gobain Life Sciences, Sartorius AG, and Thermo Fisher Scientific Inc. form the approved company scope.

Sartorius AG and Danaher Corporation, through Cytiva, compete through integrated bioprocessing portfolios spanning bioreactors, fluid management, filtration, mixing, and process-development support. Sartorius opened a 63,000-square-foot Center for Bioprocess Innovation in Marlborough, Massachusetts, in November 2024, adding customer demonstration, process-development, and service capabilities; multi-modality GMP suites were planned for 2025 ^{[7]Sartorius, Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA, sartorius.com}. Cytiva expanded its Xcellerex X-platform with 500-liter and 2,000-liter bioreactors in March 2025, extending its single-use scale range from 50 liters to 2,000 liters.

Thermo Fisher Scientific Inc. uses scale-transfer and automation compatibility to compete in bioreactor platforms. Merck KGaA combines process containers, film technologies, filtration, and process-development capabilities. Repligen Corporation's acquisition of Metenova extends its position in fluid management and mixing, while Parker Hannifin Corporation, Saint-Gobain Life Sciences, and Entegris Inc. compete in fluid handling, tubing, connectors, and critical materials.

Avantor Inc., Meissner Filtration Products Inc., and PBS Biotech Inc. address demand for qualified consumables and flexible process assemblies. Cellexus International Ltd., Celltainer Biotech BV, Eppendorf SE, and Getinge AB contribute specialized bioreactor, cell-culture, containment, and process-support capabilities. Competitive differentiation increasingly depends on supply reliability, extractables documentation, technical-service depth, and the ability to reduce risk during process transfer. The market therefore rewards both broad platform providers and specialists that occupy technically difficult workflow steps.

Recent Industry Developments

• On April 14, 2025, Thermo Fisher Scientific introduced the 5L DynaDrive Single-Use Bioreactor. The system is designed to support process development with a scale range from 1 to 5,000 liters using consistent reactor design and film, and Thermo Fisher reported a 27% productivity increase relative to glass bioreactors.
• On March 25, 2025, Cytiva expanded the Xcellerex X-platform with 500-liter and 2,000-liter single-use bioreactors, broadening its scalable offering for biologics and advanced-therapy manufacturing.
• On June 5, 2024, WuXi Biologics announced the installation of three 5,000-liter single-use bioreactors at its MFG20 facility in Hangzhou, increasing total capacity from 8,000 liters to 23,000 liters.
• On May 15, 2024, Novo Holdings announced the acquisition of an approximately 60% stake in Single Use Support, a provider of fluid-management and aliquoting technologies used in biologics, cell and gene therapy, and mRNA vaccine production.
• On September 26, 2023, Repligen announced an agreement to acquire Metenova AB, expanding its presence in single-use mixing technologies through the MixOne platform.
• On April 24, 2023, Merck KGaA launched Ultimus Single-Use Process Container Film, which it stated provides 10 times greater abrasion resistance, 2.8 times greater tensile strength, and twice the puncture strength of prior film configurations.